Loading…
Regulatory and pathogenetic mechanisms of autoantibodies in SLE
In the 53 years since the discovery of anti-DNA autoantibodies in lupus [1, 2, 3], recalcitrant questions have been pondered and possible answers have been debated. The discovery of anti-DNA autoantibodies presented many puzzles: How is immunological tolerance to native B-form DNA broken? What elici...
Saved in:
Published in: | Autoimmunity (Chur, Switzerland) Switzerland), 2011-08, Vol.44 (5), p.349-356 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3 |
container_end_page | 356 |
container_issue | 5 |
container_start_page | 349 |
container_title | Autoimmunity (Chur, Switzerland) |
container_volume | 44 |
creator | Radic, Marko Herrmann, Martin van der Vlag, Johan Rekvig, Ole Petter |
description | In the 53 years since the discovery of anti-DNA autoantibodies in lupus [1, 2, 3], recalcitrant questions have been pondered and possible answers have been debated. The discovery of anti-DNA autoantibodies presented many puzzles: How is immunological tolerance to native B-form DNA broken? What elicits characteristic systemic lupus erythematosus (SLE) autoantibodies? Which of the diverse anti-nuclear reactivities are pathogenic? What is the role of autoantibodies in the clinical presentation of disease? How do genetic predisposition and environmental triggers contribute to SLE? These questions were brought into focus by Professor David Stollar in an introductory presentation to an intense, three-day meeting set among the rugged and inspiring scenery of the Norwegian arctic coastline (the Scientific Program is included as supplemental File 1). Other participants presented and discussed topics directed to understanding the origin and clinico-pathological impact of autoantibodies to chromatin and phospholipid antigens. In the following, several aspects of the workshop are discussed. |
doi_str_mv | 10.3109/08916934.2010.536794 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1367494652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>875723439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVJaByn_6CUvaWXTaSVtB-XhmDSNGAIpA30Jmb1ESvsSq6kpfjfV4vjQi4-DRo9887wIPSZ4CtKcHeN247UHWVXFc4tTuumYx_QgtS4KVtW_T5BixkpZ-YMncf4ijGumpp9RGcVqSjJnwt086RfpgGSD7sCnCq2kDb-RTudrCxGLTfgbBxj4U0BU_Lgku29sjoW1hU_13cX6NTAEPWnt7pEz9_vfq1-lOvH-4fV7bqUjONUKlWTWpKadazvQYPCnczPnqoWc8Op4dCqikjW9poaYrA0WmLa88aA5ErSJbrc526D_zPpmMRoo9TDAE77KYq24U1FGe0y-fUoSbKpfEbNq4yyPSqDjzFoI7bBjhB2gmAxSxYHyWKWLPaS89iXtw1TP2r1f-hgNQM3e8A648MIf30YlEiwG3wwAZy0cY4_uuLbu4SNhiFtJAQtXv0UXFZ9_MZ_15qfWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367494652</pqid></control><display><type>article</type><title>Regulatory and pathogenetic mechanisms of autoantibodies in SLE</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Radic, Marko ; Herrmann, Martin ; van der Vlag, Johan ; Rekvig, Ole Petter</creator><creatorcontrib>Radic, Marko ; Herrmann, Martin ; van der Vlag, Johan ; Rekvig, Ole Petter</creatorcontrib><description>In the 53 years since the discovery of anti-DNA autoantibodies in lupus [1, 2, 3], recalcitrant questions have been pondered and possible answers have been debated. The discovery of anti-DNA autoantibodies presented many puzzles: How is immunological tolerance to native B-form DNA broken? What elicits characteristic systemic lupus erythematosus (SLE) autoantibodies? Which of the diverse anti-nuclear reactivities are pathogenic? What is the role of autoantibodies in the clinical presentation of disease? How do genetic predisposition and environmental triggers contribute to SLE? These questions were brought into focus by Professor David Stollar in an introductory presentation to an intense, three-day meeting set among the rugged and inspiring scenery of the Norwegian arctic coastline (the Scientific Program is included as supplemental File 1). Other participants presented and discussed topics directed to understanding the origin and clinico-pathological impact of autoantibodies to chromatin and phospholipid antigens. In the following, several aspects of the workshop are discussed.</description><identifier>ISSN: 0891-6934</identifier><identifier>EISSN: 1607-842X</identifier><identifier>DOI: 10.3109/08916934.2010.536794</identifier><identifier>PMID: 21231891</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Animals ; Animals, Genetically Modified ; anti-DNA antibodies ; Antibodies, Antinuclear - immunology ; Antibodies, Antinuclear - metabolism ; apoptosis ; autoantibodies ; Autoantigens - immunology ; B cell regulation ; B-Lymphocytes - cytology ; B-Lymphocytes - immunology ; B-Lymphocytes - metabolism ; Cell Death - immunology ; Disease Models, Animal ; Glomerulonephritis - etiology ; Glomerulonephritis - immunology ; Glomerulonephritis - metabolism ; Humans ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - genetics ; Lupus Erythematosus, Systemic - immunology ; Lupus Erythematosus, Systemic - therapy ; Mice ; Systemic lupus erythematosus</subject><ispartof>Autoimmunity (Chur, Switzerland), 2011-08, Vol.44 (5), p.349-356</ispartof><rights>Informa UK, Ltd. 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3</citedby><cites>FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21231891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Radic, Marko</creatorcontrib><creatorcontrib>Herrmann, Martin</creatorcontrib><creatorcontrib>van der Vlag, Johan</creatorcontrib><creatorcontrib>Rekvig, Ole Petter</creatorcontrib><title>Regulatory and pathogenetic mechanisms of autoantibodies in SLE</title><title>Autoimmunity (Chur, Switzerland)</title><addtitle>Autoimmunity</addtitle><description>In the 53 years since the discovery of anti-DNA autoantibodies in lupus [1, 2, 3], recalcitrant questions have been pondered and possible answers have been debated. The discovery of anti-DNA autoantibodies presented many puzzles: How is immunological tolerance to native B-form DNA broken? What elicits characteristic systemic lupus erythematosus (SLE) autoantibodies? Which of the diverse anti-nuclear reactivities are pathogenic? What is the role of autoantibodies in the clinical presentation of disease? How do genetic predisposition and environmental triggers contribute to SLE? These questions were brought into focus by Professor David Stollar in an introductory presentation to an intense, three-day meeting set among the rugged and inspiring scenery of the Norwegian arctic coastline (the Scientific Program is included as supplemental File 1). Other participants presented and discussed topics directed to understanding the origin and clinico-pathological impact of autoantibodies to chromatin and phospholipid antigens. In the following, several aspects of the workshop are discussed.</description><subject>Animals</subject><subject>Animals, Genetically Modified</subject><subject>anti-DNA antibodies</subject><subject>Antibodies, Antinuclear - immunology</subject><subject>Antibodies, Antinuclear - metabolism</subject><subject>apoptosis</subject><subject>autoantibodies</subject><subject>Autoantigens - immunology</subject><subject>B cell regulation</subject><subject>B-Lymphocytes - cytology</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - metabolism</subject><subject>Cell Death - immunology</subject><subject>Disease Models, Animal</subject><subject>Glomerulonephritis - etiology</subject><subject>Glomerulonephritis - immunology</subject><subject>Glomerulonephritis - metabolism</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - genetics</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Lupus Erythematosus, Systemic - therapy</subject><subject>Mice</subject><subject>Systemic lupus erythematosus</subject><issn>0891-6934</issn><issn>1607-842X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kE1rGzEQhkVJaByn_6CUvaWXTaSVtB-XhmDSNGAIpA30Jmb1ESvsSq6kpfjfV4vjQi4-DRo9887wIPSZ4CtKcHeN247UHWVXFc4tTuumYx_QgtS4KVtW_T5BixkpZ-YMncf4ijGumpp9RGcVqSjJnwt086RfpgGSD7sCnCq2kDb-RTudrCxGLTfgbBxj4U0BU_Lgku29sjoW1hU_13cX6NTAEPWnt7pEz9_vfq1-lOvH-4fV7bqUjONUKlWTWpKadazvQYPCnczPnqoWc8Op4dCqikjW9poaYrA0WmLa88aA5ErSJbrc526D_zPpmMRoo9TDAE77KYq24U1FGe0y-fUoSbKpfEbNq4yyPSqDjzFoI7bBjhB2gmAxSxYHyWKWLPaS89iXtw1TP2r1f-hgNQM3e8A648MIf30YlEiwG3wwAZy0cY4_uuLbu4SNhiFtJAQtXv0UXFZ9_MZ_15qfWw</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Radic, Marko</creator><creator>Herrmann, Martin</creator><creator>van der Vlag, Johan</creator><creator>Rekvig, Ole Petter</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201108</creationdate><title>Regulatory and pathogenetic mechanisms of autoantibodies in SLE</title><author>Radic, Marko ; Herrmann, Martin ; van der Vlag, Johan ; Rekvig, Ole Petter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Animals, Genetically Modified</topic><topic>anti-DNA antibodies</topic><topic>Antibodies, Antinuclear - immunology</topic><topic>Antibodies, Antinuclear - metabolism</topic><topic>apoptosis</topic><topic>autoantibodies</topic><topic>Autoantigens - immunology</topic><topic>B cell regulation</topic><topic>B-Lymphocytes - cytology</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - metabolism</topic><topic>Cell Death - immunology</topic><topic>Disease Models, Animal</topic><topic>Glomerulonephritis - etiology</topic><topic>Glomerulonephritis - immunology</topic><topic>Glomerulonephritis - metabolism</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - genetics</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Lupus Erythematosus, Systemic - therapy</topic><topic>Mice</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Radic, Marko</creatorcontrib><creatorcontrib>Herrmann, Martin</creatorcontrib><creatorcontrib>van der Vlag, Johan</creatorcontrib><creatorcontrib>Rekvig, Ole Petter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Autoimmunity (Chur, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Radic, Marko</au><au>Herrmann, Martin</au><au>van der Vlag, Johan</au><au>Rekvig, Ole Petter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulatory and pathogenetic mechanisms of autoantibodies in SLE</atitle><jtitle>Autoimmunity (Chur, Switzerland)</jtitle><addtitle>Autoimmunity</addtitle><date>2011-08</date><risdate>2011</risdate><volume>44</volume><issue>5</issue><spage>349</spage><epage>356</epage><pages>349-356</pages><issn>0891-6934</issn><eissn>1607-842X</eissn><abstract>In the 53 years since the discovery of anti-DNA autoantibodies in lupus [1, 2, 3], recalcitrant questions have been pondered and possible answers have been debated. The discovery of anti-DNA autoantibodies presented many puzzles: How is immunological tolerance to native B-form DNA broken? What elicits characteristic systemic lupus erythematosus (SLE) autoantibodies? Which of the diverse anti-nuclear reactivities are pathogenic? What is the role of autoantibodies in the clinical presentation of disease? How do genetic predisposition and environmental triggers contribute to SLE? These questions were brought into focus by Professor David Stollar in an introductory presentation to an intense, three-day meeting set among the rugged and inspiring scenery of the Norwegian arctic coastline (the Scientific Program is included as supplemental File 1). Other participants presented and discussed topics directed to understanding the origin and clinico-pathological impact of autoantibodies to chromatin and phospholipid antigens. In the following, several aspects of the workshop are discussed.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>21231891</pmid><doi>10.3109/08916934.2010.536794</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0891-6934 |
ispartof | Autoimmunity (Chur, Switzerland), 2011-08, Vol.44 (5), p.349-356 |
issn | 0891-6934 1607-842X |
language | eng |
recordid | cdi_proquest_miscellaneous_1367494652 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Animals Animals, Genetically Modified anti-DNA antibodies Antibodies, Antinuclear - immunology Antibodies, Antinuclear - metabolism apoptosis autoantibodies Autoantigens - immunology B cell regulation B-Lymphocytes - cytology B-Lymphocytes - immunology B-Lymphocytes - metabolism Cell Death - immunology Disease Models, Animal Glomerulonephritis - etiology Glomerulonephritis - immunology Glomerulonephritis - metabolism Humans Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - genetics Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - therapy Mice Systemic lupus erythematosus |
title | Regulatory and pathogenetic mechanisms of autoantibodies in SLE |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A57%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulatory%20and%20pathogenetic%20mechanisms%20of%20autoantibodies%20in%20SLE&rft.jtitle=Autoimmunity%20(Chur,%20Switzerland)&rft.au=Radic,%20Marko&rft.date=2011-08&rft.volume=44&rft.issue=5&rft.spage=349&rft.epage=356&rft.pages=349-356&rft.issn=0891-6934&rft.eissn=1607-842X&rft_id=info:doi/10.3109/08916934.2010.536794&rft_dat=%3Cproquest_cross%3E875723439%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-dd616c16494bbaead09cc16b3d805f53f5a8d21c48be3f1f0cfec03b57fac5dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1367494652&rft_id=info:pmid/21231891&rfr_iscdi=true |